A report by MAP BioPharma has found that NICE’s appraisal of rare disease medicines does not deliver equal access for patients. More: Report finds NICE’s routine appraisals need reform Source: News
read moreEmergex has secured a ‘state-of-the-art’ research and development (R&D) facility and hired a new chief scientific officer to drive development of its vaccines. More: Emergex to drive vaccine development with R&D facility and new hire Source: News
read moreMSD’s Keytruda in combination with Pfizer’s Inlyta has been found to reduce the risk of death by nearly half in patients with advanced renal cell carcinoma (RCC). More: Keytruda combination found to reduce risk of death in RCC Source: News
read moreNovaBiotics has been awarded £1.8 million in small business research innovation grant funding to advance its antifungal drug candidate, Novamycin. More: NovaBiotics given £1.8m to advance Novamycin Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals